Elevated levels of plasma osteoprotegerin are associated with all-cause mortality risk and atherosclerosis in patients with stages 3 to 5 chronic kidney disease

Osteoprotegerin (OPG) regulates bone mass by inhibiting osteoclast differentiation and activation, and plays a role in vascular calcification. We evaluated the relationship between osteoprotegerin levels and inflammatory markers, atherosclerosis, and mortality in patients with stages 3-5 chronic kidney disease. A total of 145 subjects (median age 61 years, 61% men; 36 patients on hemodialysis, 55 patients on peritoneal dialysis, and 54 patients with stages 3-5 chronic kidney disease) were studied. Clinical characteristics, markers of mineral metabolism (including fibroblast growth factor-23 [FGF-23]) and inflammation (high-sensitivity C-reactive protein [hsCRP] and interleukin-6 [IL-6]), and the intima-media thickness (IMT) in the common carotid arteries were measured at baseline. Cardiac function was assessed by color tissue Doppler echocardiography. After 36 months follow-up, the survival rate by Kaplan-Meier analysis was significantly different according to OPG levels (chi(2) = 14.33; P = 0.002). Increased OPG levels were positively associated with IL-6 (r = 0.38, P<0.001), FGF-23 (r = 0.26, P<0.001) and hsCRP (r = 0.0.24, P = 0.003). In addition, OPG was positively associated with troponin I (r = 0.54, P<0.001) and IMT (r = 0.39, P<0.0001). Finally, in Cox analysis, only OPG (HR = 1.07, 95% CI = 1.02-1.13) and hsCRP (HR = 1.02, 95% CI = 1.01-1.04) were independently associated with increased risk of death. These results suggested that elevated levels of serumOPG might be associated with atherosclerosis and all-cause mortality in patients with chronic kidney disease.